Kunihiko Tsuchiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kunihiko Tsuchiya has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Akimasa Tomida
Department of Pediatrics, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
7 shared publications - Eiichi Konishi
Department of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan
7 shared publications - Hideki Yoshida
Department of Pediatrics, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan
7 shared publications - Ken Kikuchi
Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602‑8566, Japan
7 shared publications - Masato Yamamoto
University of Minnesota 1 Department of Surgery Minneapolis, Minnesota
7 shared publications - Mitsuru Miyachi
Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
7 shared publications
Latest Publications
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
Background: The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow‐up study (PACI‐ON) evaluated whether these effects persisted to age 3 years. Methods: Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow‐up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician‐diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results: At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between‐group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with > 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion: Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow‐up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.
Three‐Year Follow‐Up of the PACI Randomized Controlled Trial (PACI‐ON): Effects of Early Intervention for Atopic Dermatitis on Atopic March
Background: The Prevention of Allergy via Cutaneous Intervention (PACI) randomized controlled trial (RCT) demonstrated that early enhanced topical corticosteroid (TCS) therapy modestly reduced food allergy (FA) at 28 weeks of age. The present prospective follow‐up study (PACI‐ON) evaluated whether these effects persisted to age 3 years. Methods: Participants were randomized in infancy to early enhanced (proactive) or early conventional (reactive) TCS treatment (1:1) for atopic dermatitis (AD) until 28 weeks. A total of 590 (91%) children who completed the PACI RCT were followed to age 3 years. During follow‐up, no protocolized interventions were given; all participants received usual care. Main outcomes included physician‐diagnosed FA, AD severity (EASI, POEM), sensitization profiles, allergic comorbidities, and growth parameters as safety outcomes. Results: At age 3 years, the prevalence of any FA remained lower in the early enhanced group than in the conventional group (47.4% vs. 58.8%, p = 0.006), mainly driven by a reduced prevalence of raw egg allergy (30.4% vs. 40.5%, p = 0.013). No between‐group differences were observed for wheeze, asthma, or rhinitis. Japanese cedar sensitization at age 2 was lower in the enhanced group (6.1% vs. 12.2%, p = 0.02 6) but not at age 3. AD control and quality of life were well maintained and similar across groups, with > 90% achieving mild or less disease. Early growth suppression at 1 year resolved by age 3. Conclusion: Early enhanced AD intervention was associated with a sustained modest reduction in its planned primary follow‐up outcome of FA and safety (growth) up to age 3. Although most differences were small and may reflect early diagnosis and good overall management in both groups, the findings support early AD treatment as a potential strategy to modify allergic disease trajectories.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S1 shows Map of the SALL4 promoter (pSALL4) region in human and structure of pSALL4-OAd.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S1 shows Map of the SALL4 promoter (pSALL4) region in human and structure of pSALL4-OAd.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Table S1 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S4 shows Isotype control staining
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S4 shows Isotype control staining
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
SALL4 expression in Rhabdoid Tumors in the TARGET database
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
SALL4 expression in Rhabdoid Tumors in the TARGET database
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S3 shows expression of CLDN6 and USP44 mRNA in RT cell lines
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Figure S3 shows expression of CLDN6 and USP44 mRNA in RT cell lines
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Data from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (10) , 1527-1536
A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- 19 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (10) , 1527-1536
A Novel Conditionally Replicative Oncolytic Adenovirus under the Control of the SALL4 Promoter Inhibits the Growth of Rhabdoid Tumors
Rhabdoid tumors (RT) are highly aggressive pediatric malignancies with limited treatment options. SALL4, a gene essential for embryonic stem cell pluripotency and self-renewal, is frequently overexpressed in RTs. To exploit this, we developed a conditionally replicating oncolytic adenovirus (pSALL4-OAd) by placing the E1 region under the control of the SALL4 promoter, restricting viral replication to SALL4-positive cells. SALL4 protein expression was analyzed in 10 clinical RT specimens via IHC, whereas SALL4 mRNA levels and promoter activity were assessed in eight RT cell lines using qPCR and dual-luciferase assays. The replication selectivity and cytopathic effects of pSALL4-OAd were tested in vitro at doses of 0 to 1,000 viral particles/cell. In vivo, 1.0 × 107 G401 cells were implanted subcutaneously into immunodeficient mice, followed by intratumoral administration of pSALL4-OAd (3 × 1010 viral particles) or PBS. Tumor growth was monitored over the treatment period. SALL4 protein was detected in 40% of clinical RT specimens, and RT cell lines exhibited four- to 400-fold higher SALL4 mRNA levels compared with normal tissues. Elevated SALL4 promoter activity was confirmed in three of five RT cell lines. pSALL4-OAd selectively replicated in SALL4-positive cells and induced significant cytopathic effects proportional to promoter activity in vitro. In vivo, pSALL4-OAd administration caused tumor necrosis, reduced SALL4-positive cells, and suppressed tumor proliferation. These results demonstrate the potential of pSALL4-OAd as a targeted and effective therapeutic strategy for SALL4-expressing RTs.
- Open Access
- 26 March 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (7) , 580-582
DIFENSE Study Protocol: Early Intervention With Difamilast Ointment in Infantile Early‐Onset Atopic Dermatitis for Prevention of Transcutaneous Sensitisation
- 26 March 2025
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 55 (7) , 580-582
Open AccessDIFENSE Study Protocol: Early Intervention With Difamilast Ointment in Infantile Early‐Onset Atopic Dermatitis for Prevention of Transcutaneous Sensitisation